We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Israel-based Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) is a global pharmaceutical company with a strong presence in the generics as well as branded markets. The company’s branded products include Copaxone (multiple sclerosis), Austedo (chorea associated with Huntington’s disease and tardive dyskinesia) and respiratory products like Qvar.
Teva is facing significant challenges in the form of accelerated generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business and a massive debt load. However, it has made impressive progress on restructuring activities and has a more stable financial position than before. However, we believe the company has a long way to go before it gains stability.
Teva’s earnings surpassed expectations in three the last four reported quarters, with the average positive surprise being 9.54%.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Teva’s second-quarter earnings came in at 60 cents per share which beat the consensus estimate of 58 cents.
Revenues Beat: Teva posted revenues of $4.34 billion, which beat the consensus estimate of $4.26 billion. Sales declined 8% (down 5% in constant currency terms) year over year.
Key Statistics: North America segment sales were $2.07 billion, down 8% year over year due to lower sales of Copaxone as well as Bendeka/Treanda. In the United States, revenues declined 10%year over year to $1.93 billion.
Lead branded product, Copaxone, posted sales of $274 million in North America, down 41% year over year due to generic competition in the United States. Qvar sales rose 103% to $60 million in the quarter. ProAir sales declined 44% year over year to $65 million. Generic products revenues were flat to $946 million in the quarter as additional sales from the launch of generic products made up for price erosion in the U.S business.
The Europe segment recorded revenues of $1.18 billion, down 11% (down 5% in constant currency terms) year over year. In the International Markets segment, sales declined 6% (down 2% in constant currency terms) to $741 million.
2019 Outlook Maintained: Teva re-affirmed its previously issued guidance for sales and earnings in 2019. The company expects revenues to be in the range of $17 - $17.4 billion. Meanwhile, the earnings guidance lie in a band of $2.20-2.50 per share.
Share Price Impact: Shares were up more than 1% in pre-market trading.
Teva Pharmaceutical Industries Ltd. Price and Consensus
Check back later for our full write up on this TEVA earnings report later!
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.
These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.
Image: Bigstock
Teva (TEVA) Beats Q2 Earnings & Sales Estimates, Shares Rise
Israel-based Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) is a global pharmaceutical company with a strong presence in the generics as well as branded markets. The company’s branded products include Copaxone (multiple sclerosis), Austedo (chorea associated with Huntington’s disease and tardive dyskinesia) and respiratory products like Qvar.
Teva is facing significant challenges in the form of accelerated generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business and a massive debt load. However, it has made impressive progress on restructuring activities and has a more stable financial position than before. However, we believe the company has a long way to go before it gains stability.
Teva’s earnings surpassed expectations in three the last four reported quarters, with the average positive surprise being 9.54%.
Currently, TEVA has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Teva’s second-quarter earnings came in at 60 cents per share which beat the consensus estimate of 58 cents.
Revenues Beat: Teva posted revenues of $4.34 billion, which beat the consensus estimate of $4.26 billion. Sales declined 8% (down 5% in constant currency terms) year over year.
Key Statistics: North America segment sales were $2.07 billion, down 8% year over year due to lower sales of Copaxone as well as Bendeka/Treanda. In the United States, revenues declined 10%year over year to $1.93 billion.
Lead branded product, Copaxone, posted sales of $274 million in North America, down 41% year over year due to generic competition in the United States. Qvar sales rose 103% to $60 million in the quarter. ProAir sales declined 44% year over year to $65 million. Generic products revenues were flat to $946 million in the quarter as additional sales from the launch of generic products made up for price erosion in the U.S business.
The Europe segment recorded revenues of $1.18 billion, down 11% (down 5% in constant currency terms) year over year. In the International Markets segment, sales declined 6% (down 2% in constant currency terms) to $741 million.
2019 Outlook Maintained: Teva re-affirmed its previously issued guidance for sales and earnings in 2019. The company expects revenues to be in the range of $17 - $17.4 billion. Meanwhile, the earnings guidance lie in a band of $2.20-2.50 per share.
Share Price Impact: Shares were up more than 1% in pre-market trading.
Teva Pharmaceutical Industries Ltd. Price and Consensus
Teva Pharmaceutical Industries Ltd. price-consensus-chart | Teva Pharmaceutical Industries Ltd. Quote
Check back later for our full write up on this TEVA earnings report later!
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.
These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.
Click here to see these breakthrough stocks now >>